AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BOLT

Nemec Sarah purchased $2K of BOLT

Nemec Sarah (Senior VP, Finance and PAO) purchased 509 shares of Bolt Biotherapeutics, Inc. (BOLT) at $3.88 on 2026-06-05.

Original reporting
SEC EDGAR · Nemec Sarah
Published Sep 21, 2026, 10:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 21, 2026, 10:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLT
Neutral
medium confidence
Mentioned
$BOLT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLTNeutralLow
01

Why it matters

Limited impact due to small transaction size.

02

Market read

Routine insider purchase with negligible trading relevance.

03

What to watch

Potential upcoming financing events not disclosed.

Relevance 4/10Novelty 3/10Timing: filed today

Background

Form 4 filing from SEC reveals insider transaction.

Company-level read

Ticker impact

$BOLTNeutralMedium confidence
Context

Senior VP of Finance purchased 509 shares for $1,973, a small insider buy.

Expected impact

minimal or none

Evidence & confidence

Purchase size is trivial relative to float and market cap.

Market effects

Sector

No material impact on biotech sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Even small insider buys can signal confidence, but evidence is weak.

Key entities

  • company
    Bolt Biotherapeutics, Inc.

    Biotech firm listed on NASDAQ.

  • person
    Sarah Nemec

    Senior VP of Finance at Bolt.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLT insider trading history →

Related articles

$BOLTHighAI 8/10

Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Completed acquisition of Prana Therapies and $120 million concurrent private placement financing, establishing PRA-216 and the INSPIRE-built pipeline as Bolt’s primary de

SEC EDGAR 8-K
$BOLTHigh

Bolt Biotherapeutics, Inc. (BOLT): Completion of Acquisition or Disposition of Assets

Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications • Transactions position the company to advance Prana’s pipeline of next-generation, half-lif

SEC EDGAR 8-K